EHT 0202: Completed Phase IIa enrollment

ExonHit completed enrollment of about 150 patients with mild to moderate AD in a double-blind, placebo-controlled, French Phase IIa trial evaluating 40 or 80 mg oral EHT 0202 given twice daily in comb...